Accedi

Bibliografie tematiche / Anticancer drugs / Articoli di riviste

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Anticancer drugs.

Articoli di riviste sul tema "Anticancer drugs"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 6 settembre 2023

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Anticancer drugs".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K e Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS". Indian Research Journal of Pharmacy and Science 5, n. 1 (marzo 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Reese, David M. "Anticancer drugs". Nature 378, n. 6557 (dicembre 1995): 532. http://dx.doi.org/10.1038/378532c0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs". JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, n. 1 (19 marzo 2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.

Testo completo

Abstract (sommario):

Cancer is a state of uncontrolled proliferation and dedifferentiation of cells in any tissues or organs of the body. The incidence of cancer is rising alarmingly and is one of the leading causes of morbidity and mortality globally. Normal cell division is precisely a planned biological process controlled by regulatory genes and specific metabolic pathways. Exposure of normally functioning cells to carcinogens leads to mutations in the genes causing loss of control of cell division and transform into cancerous. Over a period of time, these cancer cells acquire more mutations; invade to adjoining tissues, escape the process of apoptosis and the cells become eternal. Breakaway parts of the cancer tissues / cells travel through the lymphatic and blood vessels and get deposited in other tissues / organs leading to metastasis, the spread of cancer.

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Atkins, Joshua H., e Leland J. Gershell. "Selective anticancer drugs". Nature Reviews Drug Discovery 1, n. 7 (luglio 2002): 491–92. http://dx.doi.org/10.1038/nrd842.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Atkins, Joshua H., e Leland J. Gershell. "Selective anticancer drugs". Nature Reviews Cancer 2, n. 9 (settembre 2002): 645–46. http://dx.doi.org/10.1038/nrc900.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Bibby, M. C. "Combretastatin anticancer drugs". Drugs of the Future 27, n. 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Meegan, Mary J., e Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”". Pharmaceuticals 12, n. 3 (16 settembre 2019): 134. http://dx.doi.org/10.3390/ph12030134.

Testo completo

Abstract (sommario):

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Ciarimboli, Giuliano. "Anticancer Platinum Drugs Update". Biomolecules 11, n. 11 (4 novembre 2021): 1637. http://dx.doi.org/10.3390/biom11111637.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Zhang, Jason Y. "Apoptosis-based anticancer drugs". Nature Reviews Drug Discovery 1, n. 2 (febbraio 2002): 101–2. http://dx.doi.org/10.1038/nrd742.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Blagosklonny, Mikhail V. "Teratogens as Anticancer Drugs". Cell Cycle 4, n. 11 (22 agosto 2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

11

KOPEČEK, JINDŘICH. "Targetable Polymeric Anticancer Drugs." Annals of the New York Academy of Sciences 618, n. 1 Temporal Cont (febbraio 1991): 335–44. http://dx.doi.org/10.1111/j.1749-6632.1991.tb27253.x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

Mundy, Gregory R., e Toshiyuki Yoneda. "Bisphosphonates as Anticancer Drugs". New England Journal of Medicine 339, n. 6 (6 agosto 1998): 398–400. http://dx.doi.org/10.1056/nejm199808063390609.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Miyamoto, Shingo, Manabu Yamada, Yasuyo Kasai, Akito Miyauchi e Kazumichi Andoh. "Anticancer drugs during pregnancy". Japanese Journal of Clinical Oncology 46, n. 9 (9 giugno 2016): 795–804. http://dx.doi.org/10.1093/jjco/hyw073.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Xing, Z., D. Li, L. Yang, Y. Xi e X. Su. "MicroRNAs and anticancer drugs". Acta Biochimica et Biophysica Sinica 46, n. 3 (3 febbraio 2014): 233–39. http://dx.doi.org/10.1093/abbs/gmu003.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Wallis, Denise, James Claffey, Brendan Gleeson, Megan Hogan, Helge Müller-Bunz e Matthias Tacke. "Novel zirconocene anticancer drugs?" Journal of Organometallic Chemistry 694, n. 6 (marzo 2009): 828–33. http://dx.doi.org/10.1016/j.jorganchem.2008.08.020.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Bradley, David. "Self-assembling anticancer drugs". Materials Today 41 (dicembre 2020): 3. http://dx.doi.org/10.1016/j.mattod.2020.10.015.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Russell, Stephen J., e Kah-Whye Peng. "Viruses as anticancer drugs". Trends in Pharmacological Sciences 28, n. 7 (luglio 2007): 326–33. http://dx.doi.org/10.1016/j.tips.2007.05.005.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Kerwin, Sean. "Toward Bioengineering Anticancer Drugs". Chemistry & Biology 9, n. 9 (settembre 2002): 956–58. http://dx.doi.org/10.1016/s1074-5521(02)00222-3.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Rohr, Jürgen. "Cryptophycin Anticancer Drugs Revisited". ACS Chemical Biology 1, n. 12 (dicembre 2006): 747–50. http://dx.doi.org/10.1021/cb6004678.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Denny, William A. "Hypoxia-activated anticancer drugs". Expert Opinion on Therapeutic Patents 15, n. 6 (giugno 2005): 635–46. http://dx.doi.org/10.1517/13543776.15.6.635.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Bordon, Yvonne. "Anticancer drugs copy bugs". Nature Reviews Cancer 14, n. 12 (24 novembre 2014): 767. http://dx.doi.org/10.1038/nrc3866.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Van der Veldt, Astrid A. M., Adriaan A. Lammertsma e Egbert F. Smit. "Scheduling of anticancer drugs". Cell Cycle 11, n. 23 (dicembre 2012): 4339–43. http://dx.doi.org/10.4161/cc.22187.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Mundy, Gregory R. "Bisphosphonates as anticancer drugs". Expert Opinion on Investigational Drugs 8, n. 12 (dicembre 1999): 2009–15. http://dx.doi.org/10.1517/13543784.8.12.2009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Bordon, Yvonne. "Anticancer drugs need bugs". Nature Reviews Immunology 14, n. 1 (13 dicembre 2013): 1. http://dx.doi.org/10.1038/nri3591.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Bordon, Yvonne. "Anticancer drugs copy bugs". Nature Reviews Immunology 14, n. 12 (14 novembre 2014): 776–77. http://dx.doi.org/10.1038/nri3775.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Jefford, Michael, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson e John Zalcberg. "Discussing Expensive Anticancer Drugs". Journal of Clinical Oncology 27, n. 3 (20 gennaio 2009): 476–77. http://dx.doi.org/10.1200/jco.2008.20.1780.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Schwartsmann, G. "Anticancer drugs from nature". Medical and Pediatric Oncology 37, n. 1 (2001): 79–80. http://dx.doi.org/10.1002/mpo.1173.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis". Blood 136, Supplement 1 (5 novembre 2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.

Testo completo

Abstract (sommario):

Introduction Anticancer treatments has been changing since decades, evolving from chemotherapy (platinum salts) to recent check-point inhibitors. Nausea, vomiting and diarrhoea are common adverse events of anticancer drugs, despites the fact that some supportive care drugs can manage these adverse events. Gastro-intestinal (GI) disorders/toxicities are also important. Such as gastric/duodenal ulcer, gastritis, stomatitis, colitis, esophagitis... Cancer-associated-thrombosis (CAT) patients were also reported to be exposed to such GI disorders/toxicities and several publications recommended to consider these GI disorders/toxicities when choosing an anticoagulant in CAT (Carrier M. Curr Oncol 2018; Moik F. ESMO Open 2020). However, little is known about the nature of the anticancer drugs that CAT patients are receiving. The aim of this work was to check all the anticancer's SmPCs (Summary of Product Characteristics) on the EMA website for GI disorders. Methods All SmPCs of anticancer drugs indicated for lung cancer were checked on the EMA website. All adverse events regarding GI disorders/toxicities were collected. The frequency of adverse events used was the following: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000). However, it was decided to mainly focus on very common and common ones. Old anticancer drugs SmPCs (platinium salts...) were checked on electronic medicines compendium (medicines.org.uk), because these old SmPCs are not always available on the EMA website. Generics, biosimilars and drugs without a licence were excluded. Results Twenty-eight anticancer drugs were identified with a mix of traditional chemotherapies (platinum salts...), tyrosine kinase inhibitors (nib) and monoclonal antibodies (mab). Among these 28 anticancer drugs, 26 had at least one very common/common GI disorders/toxicities. Obviously, vomiting (82.1%) and diarrhoea (89.3%) are very well-known, but it was interesting to see that many anticancer drugs were associated with other very common/common GI toxicities such as stomatitis (71.4%) and colitis (10.7%). Additionally, several drugs (35.7%) were exposing to GI bleeding and/or GI perforation but these last adverse events were less common. Unfortunately, the SmPCs did not include data about the GI profile of the patients during the trials. Conclusion Monreal M et al reported in 1991 that acute gastroduodenal lesion was found in 21% of patients with venous thromboembolism, but there are no dedicated study about the incidence of GI disorders in CAT patients. This work reported that GI disorders/toxicities were common in anticancer drug's SmPCs. Consequently, it is important to be aware of this before initiating an anticoagulant treatment. However, this work had limitations. Indeed, these adverse events were reported in the SmPCs, based mainly on cancer trials and not on CAT trials. Furthermore, clinical trials and SmPCs may not always reflect the real clinical setting. Finally, lung cancer patients are usually receiving anticancer regimens that include several anticancer drugs, so the potential impact of GI disorders/toxicities from 2 or 3 anticancer drugs on a single patients could be greater. Nevertheless, it sounds reasonable to check for GI disorders/toxicities risks in order to initiate an adequate anticoagulant treatment in CAT patients and during follow-up. Disclosures Janus: Guerbet:Research Funding;B-Braun:Honoraria;LEO Pharma A/S:Current Employment, Honoraria;Fresenius Medical Care:Honoraria;Amgen:Honoraria, Research Funding;TEVA:Research Funding;Daichii-Sankyo:Honoraria, Research Funding;Roche:Honoraria, Research Funding;Vifor Pharma:Honoraria, Research Funding;Gilead:Honoraria, Research Funding;Novartis:Honoraria;Pierre Fabre Oncology:Research Funding;Bayer:Honoraria, Research Funding;Pfizer:Consultancy, Honoraria;IPSEN:Honoraria.

Gli stili APA, Harvard, Vancouver, ISO e altri

29

Li, Dong Hong, Jun Lin Diao, Ke Gui Yu e Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs". Chinese Chemical Letters 18, n. 11 (novembre 2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

&NA;. "Anticancer drugs from the sea". Inpharma Weekly &NA;, n. 1417 (dicembre 2003): 4. http://dx.doi.org/10.2165/00128413-200314170-00007.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Evans, William E., e Mary V. Relling. "Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs". Clinical Pharmacokinetics 16, n. 6 (giugno 1989): 327–36. http://dx.doi.org/10.2165/00003088-198916060-00001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Carcone, Bernard, e Dionyssis Pongas. "Cardiovascular toxicity of anticancer drugs". Sang thrombose vaisseaux 26, n. 4 (luglio 2014): 188–96. http://dx.doi.org/10.1684/stv.2014.0849.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Amelio, Ivano, Andrey Lisitsa, Richard Knight, Gerry Melino e Alexey Antonov. "Polypharmacology of Approved Anticancer Drugs". Current Drug Targets 18, n. 5 (24 febbraio 2017): 534–43. http://dx.doi.org/10.2174/1389450117666160301095233.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner e William D. Figg. "Thalidomide Analogues as Anticancer Drugs". Recent Patents on Anti-Cancer Drug Discovery 2, n. 2 (1 giugno 2007): 167–74. http://dx.doi.org/10.2174/157489207780832478.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

35

Meegan, Mary J., e Niamh M. O’Boyle. "Special Issue “Anticancer Drugs 2021”". Pharmaceuticals 15, n. 4 (14 aprile 2022): 479. http://dx.doi.org/10.3390/ph15040479.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey e Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs". Current Topics in Medicinal Chemistry 11, n. 5 (1 marzo 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

Fujita, Ken-ichi. "Cytochrome P450 and Anticancer Drugs". Current Drug Metabolism 7, n. 1 (1 gennaio 2006): 23–37. http://dx.doi.org/10.2174/138920006774832587.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Wallace, H. M., e A. V. Fraser. "Polyamine analogues as anticancer drugs". Biochemical Society Transactions 31, n. 2 (1 aprile 2003): 393–96. http://dx.doi.org/10.1042/bst0310393.

Testo completo

Abstract (sommario):

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer cells, and consequently the identification of their metabolic pathways as a target for therapeutic intervention, led to the development of a number of useful inhibitors of polyamine biosynthesis. Arguably the most significant addition to the polyamine field in the last 30 years was the synthesis of α-difluoromethylornithine (DFMO), which is being tested currently as a cancer chemopreventative agent in man and is used also as a highly effective trypanocidal agent. Although an extremely useful tool experimentally, DFMO has been disappointing in clinical trials with little therapeutic efficacy. Despite this setback, the polyamine pathway is still considered a viable target for chemotherapeutic intervention. This has led to the development of the polyamine analogues as multifunctional inhibitors that will produce inhibition of tumour cell growth, polyamine depletion and optimum therapeutic efficacy.

Gli stili APA, Harvard, Vancouver, ISO e altri

39

Hyodo, Kenji, Eiichi Yamamoto, Takuya Suzuki, Hiroshi Kikuchi, Makoto Asano e Hiroshi Ishihara. "Development of Liposomal Anticancer Drugs". Biological and Pharmaceutical Bulletin 36, n. 5 (2013): 703–7. http://dx.doi.org/10.1248/bpb.b12-01106.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

40

Powis, Garth, Miles P. Hacker e Graziano C. Carlon. "The Toxicity of Anticancer Drugs". Critical Care Medicine 21, n. 7 (luglio 1993): 1101. http://dx.doi.org/10.1097/00003246-199307000-00034.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

41

Baumann, F., e R. Preiss. "Cyclophosphamide and related anticancer drugs". Journal of Chromatography B: Biomedical Sciences and Applications 764, n. 1-2 (novembre 2001): 173–92. http://dx.doi.org/10.1016/s0378-4347(01)00279-1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

42

Tjaden, U. R., e E. A. De Bruijn. "Chromatographic analysis of anticancer drugs". Journal of Chromatography B: Biomedical Sciences and Applications 531 (ottobre 1990): 235–94. http://dx.doi.org/10.1016/s0378-4347(00)82286-0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Sapra, P., e T. M. Allen. "Ligand-targeted liposomal anticancer drugs". Progress in Lipid Research 42, n. 5 (settembre 2003): 439–62. http://dx.doi.org/10.1016/s0163-7827(03)00032-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

44

Tanigawara, Y. "Pharmaco-Metabolomics for Anticancer Drugs". Annals of Oncology 23 (ottobre 2012): xi55. http://dx.doi.org/10.1016/s0923-7534(20)32076-7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

45

Yoshioka, T. "Drugs Interaction of Anticancer Agents". Annals of Oncology 23 (ottobre 2012): xi65. http://dx.doi.org/10.1016/s0923-7534(20)32111-6.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

46

Muers, Mary. "Transgenerational effects of anticancer drugs". Nature Reviews Genetics 13, n. 3 (14 febbraio 2012): 148. http://dx.doi.org/10.1038/nrg3190.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

47

Gosland, Michael P., e Bert L. Lum. "The Anticancer Drugs, 2nd Edition". Annals of Pharmacotherapy 29, n. 3 (marzo 1995): 320. http://dx.doi.org/10.1177/106002809502900321.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Meyer, G. "Pulmonary Toxicity of Anticancer Drugs". Annals of Oncology 25 (settembre 2014): iv33. http://dx.doi.org/10.1093/annonc/mdu310.2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

49

Imran, Muhammad, Wagma Ayub, Ian S. Butler e Zia-ur-Rehman. "Photoactivated platinum-based anticancer drugs". Coordination Chemistry Reviews 376 (dicembre 2018): 405–29. http://dx.doi.org/10.1016/j.ccr.2018.08.009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

SALVIK, MILAN, JUN WU e CHRISTOPHER RILEY. "Salivary Excretion of Anticancer Drugs". Annals of the New York Academy of Sciences 694, n. 1 Saliva as a D (settembre 1993): 319–21. http://dx.doi.org/10.1111/j.1749-6632.1993.tb18377.x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!